<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="34f4eb14-b40e-1d6d-e063-6394a90a3e3b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE OPHTHALMIC SOLUTION, 0.3%/0.4% safely and effectively. See full prescribing information for FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE OPHTHALMIC SOLUTION, 0.3%/0.4%.
 <br/>
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE OPHTHALMIC SOLUTION, 0.3%/0.4%, for topical ophthalmic use
 <br/>
Initial U.S. Approval: 2017
</title>
   <effectiveTime value="20250512"/>
   <setId root="1797c5ef-66c4-4cf8-b62d-b484242be2ee"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="196603781"/>
            <name>Bausch &amp; Lomb Incorporated</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="102688657"/>
                        <name>Alliance Medical Products, Inc. (dba Siegfried Irvine)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="24208-734" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="34f4d2d5-11a5-0231-e063-6294a90ab796"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250512"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="24208-734" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Fluorescein Sodium and Benoxinate Hydrochloride</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Fluorescein Sodium and Benoxinate Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.6"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="93X55PE38X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FLUORESCEIN SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TPY09G7XIR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FLUORESCEIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="4.4"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0VE4U49K15" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENOXINATE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="AXQ0JYM303" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BENOXINATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43172" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="24208-734-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20200320"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA211039" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200320"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_49d992f5-06f0-489a-851f-e393d01317cd">
               <id root="34f4eb14-b40f-1d6d-e063-6394a90a3e3b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent.</paragraph>
               </text>
               <effectiveTime value="20220831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is a combination of fluorescein sodium, a disclosing agent and benoxinate hydrochloride, a local ester anesthetic indicated for procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic. (
 
    <linkHtml href="#_RefID_49d992f5-06f0-489a-851f-e393d0131">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_950f47a1-47f1-4207-8a9f-045b0b5a0693">
               <id root="34f4eb14-b410-1d6d-e063-6394a90a3e3b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Instill 1 to 2 drops topically in the eye as needed.</paragraph>
               </text>
               <effectiveTime value="20220831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Instill 1 to 2 drops topically in the eye as needed to achieve adequate anesthesia. (
 
    <linkHtml href="#_RefID_950f47a1-47f1-4207-8a9f-045b0b5a0">2</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_f4a0d2b3-8963-4788-b7fb-55476eee7d2e">
               <id root="34f4eb14-b411-1d6d-e063-6394a90a3e3b"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is a yellow to orange-red ophthalmic solution containing fluorescein sodium 2.6 mg/mL (0.3%) and benoxinate hydrochloride 4.4 mg/mL (0.4%).</paragraph>
               </text>
               <effectiveTime value="20220831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic solution containing fluorescein sodium 2.6 mg/mL (0.3%) and benoxinate hydrochloride 4.4 mg/mL (0.4%). (
 
    <linkHtml href="#_RefID_f4a0d2b3-8963-4788-b7fb-55476eee7">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_fb09dcd8-3608-4499-9668-4536a429836e">
               <id root="34f4eb14-b412-1d6d-e063-6394a90a3e3b"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is contraindicated in patients with known hypersensitivity to any component of this product.</paragraph>
               </text>
               <effectiveTime value="20220831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Known hypersensitivity to any component of this product. (
 
    <linkHtml href="#_RefID_fb09dcd8-3608-4499-9668-4536a4298">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_8cbc778b-192d-4fd1-80ed-d8b7be2b30b7">
               <id root="34f4eb14-b413-1d6d-e063-6394a90a3e3b"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20220831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Corneal Toxicity</content>: Prolonged use or abuse may lead to corneal epithelial toxicity and manifest as epithelial defects which may progress to permanent corneal damage. (
  
     <content styleCode="bold">Error! Hyperlink reference not valid.</content>)
 
    </item>
                           <item>
                              <content styleCode="underline">Corneal Injury</content>: Patients should not touch the eye for approximately 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. (
  
     <linkHtml href="#ID_8734d2fe-ca51-44b7-a0b3-9a78ed05ef4f">5.2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_000eb365-eaa0-4c76-9303-56f56d138a0c">
                     <id root="34f4eb14-b414-1d6d-e063-6394a90a3e3b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Corneal Toxicity</title>
                     <text>
                        <paragraph>Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage with accompanying visual loss.</paragraph>
                     </text>
                     <effectiveTime value="20220831"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8734d2fe-ca51-44b7-a0b3-9a78ed05ef4f">
                     <id root="34f4eb14-b415-1d6d-e063-6394a90a3e3b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Corneal Injury Due to Insensitivity</title>
                     <text>
                        <paragraph>Patients should not touch the eye for approximately 20 minutes after using this anesthetic as accidental injuries can occur due to insensitivity of the eye.</paragraph>
                     </text>
                     <effectiveTime value="20220831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a4a0a7b6-880c-42c9-b780-24818e36c1dc">
               <id root="34f4eb14-b416-1d6d-e063-6394a90a3e3b"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious ocular adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Corneal Toxicity
  
   <content styleCode="italics">[see
   
    <linkHtml href="#ID_000eb365-eaa0-4c76-9303-56f56d138a0c">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>Corneal Injury Due to Insensitivity
  
   <content styleCode="italics">[see
   
    <linkHtml href="#ID_8734d2fe-ca51-44b7-a0b3-9a78ed05ef4f">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions have been identified following use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4%: ocular hyperemia, burning, stinging, eye irritation, blurred vision and punctate keratitis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
               </text>
               <effectiveTime value="20220831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common ocular adverse events are: stinging, burning and conjunctival redness. (
 
    <linkHtml href="#_RefID_a4a0a7b6-880c-42c9-b780-24818e36c">6)</linkHtml>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Bausch &amp; Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or
  
     <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_af6b7f56-38ec-4cfc-addd-48ccea527df5">
               <id root="34f4eb14-b417-1d6d-e063-6394a90a3e3b"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20220831"/>
               <component>
                  <section ID="ID_4ddf60c1-056b-458b-ae72-4ba7f865d115">
                     <id root="34f4eb14-b418-1d6d-e063-6394a90a3e3b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on the use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% in pregnant women to inform any drug associated risk.</paragraph>
                        <paragraph>Adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% should be given to a pregnant woman only if clearly needed.</paragraph>
                     </text>
                     <effectiveTime value="20220831"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7ccc719e-0163-4a2b-8809-36bca001a0d3">
                     <id root="34f4eb14-b419-1d6d-e063-6394a90a3e3b"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4%, the effects on the breastfed infant, or the effects on milk production.</paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4%, and any potential adverse effects on the breastfed infant from Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4%.</paragraph>
                     </text>
                     <effectiveTime value="20220831"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_220d0acd-307e-42d1-a091-67e312b7f5e0">
                     <id root="34f4eb14-b41a-1d6d-e063-6394a90a3e3b"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% have been established for pediatric patients. Use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is supported in pediatric patients by evidence from adequate and well controlled studies.</paragraph>
                     </text>
                     <effectiveTime value="20220831"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4500ca8d-ec7f-40f1-ab02-c1d911668853">
                     <id root="34f4eb14-b41b-1d6d-e063-6394a90a3e3b"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20220831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c5750b69-814f-4aab-b4c7-dd76be12ca6e">
               <id root="34f4eb14-b41c-1d6d-e063-6394a90a3e3b"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is a sterile solution containing a disclosing agent in combination with a short-acting ester anesthetic for topical ophthalmic use.</paragraph>
                  <paragraph>Fluorescein sodium is represented by the following structural formula:</paragraph>
                  <renderMultiMedia ID="id-1097319636" referencedObject="A8F514CB-770C-4690-993F-743310D98FC1"/>
                  <paragraph>Chemical Name: 3’,6’ Dihydroxy-3H-spiro[isobenzofuran-1,9-xanthen]-3-one disodium salt.</paragraph>
                  <paragraph>Benoxinate hydrochloride is represented by the following structural formula:</paragraph>
                  <renderMultiMedia ID="id2065983320" referencedObject="ID_957e5940-7388-4b95-a761-76232293978a"/>
                  <paragraph>Chemical Name: 2-(Diethylamino) ethyl 4-amino-3-butoxybenzoate hydrochloride.</paragraph>
                  <paragraph>Each mL of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution 0.3%/0.4% contains:</paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="underline">Active ingredients:</content>fluorescein sodium 2.6 mg (0.3%) equivalent to fluorescein 2.3 mg (0.2%), benoxinate hydrochloride 4.4 mg (0.4%) equivalent to benoxinate 3.9 mg (0.4%)
 
  </item>
                     <item>
                        <content styleCode="underline">Preservative:</content>chlorobutanol 12.6 mg (1.3%)
 
  </item>
                     <item>
                        <content styleCode="underline">Inactive ingredients:</content>povidone, hydrochloric acid, boric acid, water for injection. Hydrochloric acid may be added to adjust pH (4.3 – 5.3).
 
  </item>
                  </list>
               </text>
               <effectiveTime value="20220831"/>
               <component>
                  <observationMedia ID="A8F514CB-770C-4690-993F-743310D98FC1">
                     <text>ChemFluorescein</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_957e5940-7388-4b95-a761-76232293978a">
                     <text>ChemBenoxinate</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_cd0a8229-2d90-47b8-9ed5-776cdfd86d97">
               <id root="34f4eb14-b41d-1d6d-e063-6394a90a3e3b"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20220831"/>
               <component>
                  <section ID="ID_589c78ff-455e-4ee0-86bd-1981420cc1b1">
                     <id root="34f4eb14-b41e-1d6d-e063-6394a90a3e3b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration. The anesthetic effect may be extended by subsequent administration 10-20 minutes after the last administration.</paragraph>
                     </text>
                     <effectiveTime value="20220831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8808b0ab-e098-4cbc-acab-bdfdf8d98217">
               <id root="34f4eb14-b41f-1d6d-e063-6394a90a3e3b"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20220831"/>
               <component>
                  <section ID="ID_5ae3fed5-9c56-4168-b4fd-97b28a45c794">
                     <id root="34f4eb14-b420-1d6d-e063-6394a90a3e3b"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Studies to evaluate the mutagenic or carcinogenic potential of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% have not been conducted. Studies to evaluate impairment of fertility have not been conducted.</paragraph>
                     </text>
                     <effectiveTime value="20220831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_2a3b8022-ed28-474f-adc1-f593be435d5e">
               <id root="34f4eb14-b421-1d6d-e063-6394a90a3e3b"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Controlled clinical studies in adults and pediatric patients have demonstrated that topical administration of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% enables visualization and corneal anesthesia sufficient to enable applanation tonometry, tear fluid dynamics evaluation and short conjunctival and corneal procedures. Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration.</paragraph>
               </text>
               <effectiveTime value="20220831"/>
            </section>
         </component>
         <component>
            <section ID="ID_2eb643aa-04b7-4e18-88b7-3cbf32319c80">
               <id root="34f4eb14-b422-1d6d-e063-6394a90a3e3b"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is supplied as a sterile, aqueous, topical ophthalmic solution with a fill volume of 5 mL in a 6 mL amber glass bottle and a black polypropylene cap with a sterilized rubber dropper bulb and glass pipette.</paragraph>
                  <paragraph>NDC 24208-734-05</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content>Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. After opening, can be stored up to one month if stored at room temperature or until the expiration date on the bottle if stored in refrigerated conditions. Keep tightly closed.

 </paragraph>
               </text>
               <effectiveTime value="20220831"/>
            </section>
         </component>
         <component>
            <section ID="ID_d6cfc4c4-d6a2-4ae4-9f85-405ed0c80560">
               <id root="34f4eb14-b423-1d6d-e063-6394a90a3e3b"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Accidental Injury Precaution</content>
                  </paragraph>
                  <paragraph>Advise patients not to touch their eyes for approximately 20 minutes after application. Their eyes will be insensitive due to the effect of the anesthetic, and care should be taken to avoid accidental injuries.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                     <br/>  Bausch &amp; Lomb Americas Inc. 
  <br/>  Bridgewater, NJ 08807 USA

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                     <br/>  Siegfried-Irvine 
  <br/>  Irvine, CA 92618 USA

 </paragraph>
                  <paragraph>Patented. See
 
  <linkHtml href="https://patents.bausch.com">https://patents.bausch.com</linkHtml>for US patent information.

 </paragraph>
                  <paragraph>© 2022 Bausch &amp; Lomb Incorporated or its affiliates</paragraph>
                  <paragraph>9785500</paragraph>
               </text>
               <effectiveTime value="20220831"/>
            </section>
         </component>
         <component>
            <section ID="ID_3eb5cb53-78a4-424d-a479-6fd9b50044df">
               <id root="34f4eb14-b424-1d6d-e063-6394a90a3e3b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC</content>24208-734-05

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Fluorescein Sodium</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">and Benoxinate</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Hydrochloride</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Ophthalmic Solution</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">0.3%/0.4%</content>
                  </paragraph>
                  <paragraph>(Sterile)</paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR TOPICAL OPHTHALMIC USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">[Eye Image]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                     <content styleCode="bold">5 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">BAUSCH + LOMB</content>
                  </paragraph>
                  <paragraph>9785301</paragraph>
                  <renderMultiMedia ID="id2131050370" referencedObject="ID_60e5e8b4-a588-4dd3-9e50-2846771d42dd"/>
               </text>
               <effectiveTime value="20220831"/>
               <component>
                  <observationMedia ID="ID_60e5e8b4-a588-4dd3-9e50-2846771d42dd">
                     <text>carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>